Chronic inflammatory activation in fat tissue: an atherogenic factor in severe coronary artery disease.

INTERVENTION: Trade Name: Glucophage 850mg Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: METFORMIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 662.9‐ Trade Name: Januvia 100mg Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: Sitagliptin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ CONDITION: severe cardiovascular artery disease PRIMARY OUTCOME: Main Objective: change in endothelial function in severe coronary artery disease Primary end point(s): Change in endothelial function Secondary Objective: change in metabolic parameters INCLUSION CRITERIA: ‐either impaired glucose tolerance (2h plasma glucose concentration >7.8 and <11.1mmol/L during an oral glucose tolerance test) or impaired fasting plasma glucose concentration (>6.0 and <7.0mmol/L) ‐BMI >25 ‐severe coronary artery disease determined by coronary angiography ‐male patients aged 35‐75 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range